S&P 500   4,286.76 (-0.03%)
DOW   33,403.12 (-0.31%)
QQQ   359.97 (+0.47%)
AAPL   173.04 (+1.07%)
MSFT   317.43 (+0.53%)
META   304.82 (+1.54%)
GOOGL   132.80 (+1.48%)
AMZN   128.21 (+0.86%)
TSLA   246.06 (-1.66%)
NVDA   446.38 (+2.62%)
NIO   8.80 (-2.65%)
BABA   86.27 (-0.54%)
AMD   103.31 (+0.48%)
T   14.95 (-0.47%)
F   12.38 (-0.32%)
MU   68.77 (+1.09%)
CGC   0.77 (-1.70%)
GE   110.18 (-0.33%)
DIS   80.91 (-0.17%)
AMC   8.33 (+4.26%)
PFE   33.37 (+0.60%)
PYPL   59.25 (+1.35%)
NFLX   380.49 (+0.77%)
S&P 500   4,286.76 (-0.03%)
DOW   33,403.12 (-0.31%)
QQQ   359.97 (+0.47%)
AAPL   173.04 (+1.07%)
MSFT   317.43 (+0.53%)
META   304.82 (+1.54%)
GOOGL   132.80 (+1.48%)
AMZN   128.21 (+0.86%)
TSLA   246.06 (-1.66%)
NVDA   446.38 (+2.62%)
NIO   8.80 (-2.65%)
BABA   86.27 (-0.54%)
AMD   103.31 (+0.48%)
T   14.95 (-0.47%)
F   12.38 (-0.32%)
MU   68.77 (+1.09%)
CGC   0.77 (-1.70%)
GE   110.18 (-0.33%)
DIS   80.91 (-0.17%)
AMC   8.33 (+4.26%)
PFE   33.37 (+0.60%)
PYPL   59.25 (+1.35%)
NFLX   380.49 (+0.77%)
S&P 500   4,286.76 (-0.03%)
DOW   33,403.12 (-0.31%)
QQQ   359.97 (+0.47%)
AAPL   173.04 (+1.07%)
MSFT   317.43 (+0.53%)
META   304.82 (+1.54%)
GOOGL   132.80 (+1.48%)
AMZN   128.21 (+0.86%)
TSLA   246.06 (-1.66%)
NVDA   446.38 (+2.62%)
NIO   8.80 (-2.65%)
BABA   86.27 (-0.54%)
AMD   103.31 (+0.48%)
T   14.95 (-0.47%)
F   12.38 (-0.32%)
MU   68.77 (+1.09%)
CGC   0.77 (-1.70%)
GE   110.18 (-0.33%)
DIS   80.91 (-0.17%)
AMC   8.33 (+4.26%)
PFE   33.37 (+0.60%)
PYPL   59.25 (+1.35%)
NFLX   380.49 (+0.77%)
S&P 500   4,286.76 (-0.03%)
DOW   33,403.12 (-0.31%)
QQQ   359.97 (+0.47%)
AAPL   173.04 (+1.07%)
MSFT   317.43 (+0.53%)
META   304.82 (+1.54%)
GOOGL   132.80 (+1.48%)
AMZN   128.21 (+0.86%)
TSLA   246.06 (-1.66%)
NVDA   446.38 (+2.62%)
NIO   8.80 (-2.65%)
BABA   86.27 (-0.54%)
AMD   103.31 (+0.48%)
T   14.95 (-0.47%)
F   12.38 (-0.32%)
MU   68.77 (+1.09%)
CGC   0.77 (-1.70%)
GE   110.18 (-0.33%)
DIS   80.91 (-0.17%)
AMC   8.33 (+4.26%)
PFE   33.37 (+0.60%)
PYPL   59.25 (+1.35%)
NFLX   380.49 (+0.77%)
NASDAQ:EVAX

Evaxion Biotech A/S (EVAX) Stock Forecast, Price & News

$0.86
+0.03 (+3.24%)
(As of 09:39 AM ET)
Compare
Today's Range
$0.86
$0.88
50-Day Range
$0.48
$1.27
52-Week Range
$0.47
$3.10
Volume
3,573 shs
Average Volume
314,662 shs
Market Capitalization
$23.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Evaxion Biotech A/S MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
980.4% Upside
$9.00 Price Target
Short Interest
Healthy
0.88% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Evaxion Biotech A/S in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

616th out of 968 stocks

Biological Products, Except Diagnostic Industry

90th out of 161 stocks


EVAX stock logo

About Evaxion Biotech A/S (NASDAQ:EVAX) Stock

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Hørsholm, Denmark.

EVAX Price History

EVAX Stock News Headlines

Evaxion Biotech A/S (NASDAQ:EVAX) Stock Price Down 3.7%
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Nuclear Revival Creates Opportunities for Uranium
Uranium companies set to benefit from increased demand for clean energy.
Q2 2023 Evaxion Biotech A/S Earnings Call
Evaxion gets $20M financing from Negma
Why Are Evaxion Biotech Shares Trading Higher Today
See More Headlines
Receive EVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evaxion Biotech A/S and its competitors with MarketBeat's FREE daily newsletter.

EVAX Company Calendar

Last Earnings
8/22/2023
Today
10/01/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EVAX
Fax
N/A
Employees
63
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+980.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-23,170,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.35 per share

Miscellaneous

Free Float
16,138,000
Market Cap
$23.03 million
Optionable
Not Optionable
Beta
0.53
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Niels Iversen Moeller M.D. (Age 44)
    Co-Founder, VP of Bus. & Director
    Comp: $120k
  • Mr. Andreas Holm Mattsson (Age 47)
    Co-Founder and Chief AI & Culture Officer
    Comp: $319k
  • Mr. Jesper Nyegaard Nissen (Age 53)
    CFO & COO
    Comp: $346.97k
  • Dr. Birgitte Rono Ph.D. (Age 47)
    Chief Scientific Officer
    Comp: $336k
  • Mr. Christian Kanstrup (Age 51)
    Chief Exec. Officer
  • Dr. Jürgen Langhärig EMBA
    Ph.D., Head of Bus. Devel. & Member of Advisory Board













EVAX Stock - Frequently Asked Questions

Should I buy or sell Evaxion Biotech A/S stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evaxion Biotech A/S in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EVAX shares.
View EVAX analyst ratings
or view top-rated stocks.

What is Evaxion Biotech A/S's stock price forecast for 2023?

2 brokerages have issued 1 year target prices for Evaxion Biotech A/S's stock. Their EVAX share price forecasts range from $7.00 to $11.00. On average, they anticipate the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 980.4% from the stock's current price.
View analysts price targets for EVAX
or view top-rated stocks among Wall Street analysts.

How have EVAX shares performed in 2023?

Evaxion Biotech A/S's stock was trading at $1.7750 at the beginning of 2023. Since then, EVAX stock has decreased by 53.1% and is now trading at $0.8330.
View the best growth stocks for 2023 here
.

Are investors shorting Evaxion Biotech A/S?

Evaxion Biotech A/S saw a increase in short interest in September. As of September 15th, there was short interest totaling 242,800 shares, an increase of 38.5% from the August 31st total of 175,300 shares. Based on an average trading volume of 112,500 shares, the short-interest ratio is currently 2.2 days.
View Evaxion Biotech A/S's Short Interest
.

When is Evaxion Biotech A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our EVAX earnings forecast
.

How were Evaxion Biotech A/S's earnings last quarter?

Evaxion Biotech A/S (NASDAQ:EVAX) posted its quarterly earnings data on Tuesday, August, 22nd. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.01.

When did Evaxion Biotech A/S IPO?

(EVAX) raised $31 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 2,800,000 shares at a price of $10.00-$12.00 per share. Oppenheimer & Co. acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

What is Evaxion Biotech A/S's stock symbol?

Evaxion Biotech A/S trades on the NASDAQ under the ticker symbol "EVAX."

How do I buy shares of Evaxion Biotech A/S?

Shares of EVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evaxion Biotech A/S's stock price today?

One share of EVAX stock can currently be purchased for approximately $0.83.

How much money does Evaxion Biotech A/S make?

Evaxion Biotech A/S (NASDAQ:EVAX) has a market capitalization of $23.03 million. The company earns $-23,170,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis.

How can I contact Evaxion Biotech A/S?

Evaxion Biotech A/S's mailing address is BREDGADE 34E, COPENHAGEN K G7, 1260. The official website for the company is www.evaxion-biotech.com. The company can be reached via phone at 45-5353-1850 or via email at info@evaxion-biotech.com.

This page (NASDAQ:EVAX) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -